Kingdomway(SZ:002626) Xin Lang Cai Jing·2025-08-28 03:41Core Viewpoint - The issuance of "Jinwei Convertible Bonds" has a remarkably low subscription rate of 0.0024%, making it one of the most difficult bonds to acquire this year. The bond issuance is part of the company's expansion plan, but it is overshadowed by declining profit margins and increasing debt levels [1][2]. Fundraising and Strategic Expansion - Jinwei raised 1.292 billion yuan through the issuance of convertible bonds, marking its largest refinancing move in recent years. The high proportion of preferential allocation to existing shareholders (83.49%) indicates strong confidence from major shareholders, while also serving to protect their control [2][3]. - Approximately 60% of the raised funds will be directed towards specific construction projects, with a significant focus on expanding the production capacity of its flagship product, coenzyme Q10, and investing over 460 million yuan in new product areas such as allulose and inositol [2][3]. Financial Performance and Concerns - In the first half of 2025, Jinwei reported a revenue of 1.728 billion yuan, a year-on-year increase of 13.46%, and a net profit of 247 million yuan, up 90.12% [5]. - Despite the apparent growth, the company faces challenges regarding the quality of its earnings and assets, with a notable decline in the profitability of its core products [6][7]. - The gross margin of coenzyme Q10 has decreased from 77.57% in 2020 to 48.2% in 2024, indicating a loss of competitive advantage [10][13]. Debt and Cash Flow Issues - Jinwei's total liabilities reached 2.303 billion yuan in the first quarter of this year, a significant year-on-year increase of 48.74%. The company has experienced rapid debt growth for two consecutive years [14][15]. - The company has seen a sharp rise in short-term debt, with short-term borrowings increasing from 58 million yuan in 2023 to 661 million yuan in the first half of this year, reflecting a 252% increase [14][15]. - Cash flow from investment activities has been negative for four consecutive years, totaling 1.307 billion yuan, indicating financial strain due to aggressive expansion strategies [16]. Market Risks and Strategic Challenges - Jinwei's expansion into unfamiliar product areas such as allulose and inositol poses significant risks, as the company has not previously marketed these products [4]. - The sweetener market is highly competitive, and Jinwei's ability to capture market share as a latecomer remains uncertain, raising concerns about the synergy with its core business [4]. - The company has accumulated goodwill of 515 million yuan, which constitutes 11.9% of its net assets, primarily from acquisitions of overseas brands. However, there are risks of goodwill impairment if these acquisitions do not meet performance expectations [18][19]. Currency and Economic Exposure - Jinwei's overseas revenue reached 2.566 billion yuan in 2024, accounting for 79.2% of total revenue, making it vulnerable to currency fluctuations, particularly with the depreciation of the US dollar against the yuan [22]. - The company has benefited from foreign exchange gains in recent years, but potential shifts in currency trends could lead to losses, impacting overall profitability [22].